Notícias e Atividades da Apollomics

Apollomics é uma empresa listada sob o símbolo APLM (US).

Veja o organograma con seus 15 executivos principais

Biografias mais buscadas da Apollomics

• Howard Chen, Chief Executive Officer and Chairman of the Board
• Moses Chen, Independent Director
• Frank Chu, Independent Director

Recentes movimentos de executivos em Apollomics

• Claudia Huang, ingressou na Companhia como Independent Director  (Notícia publicada em 18 de novembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da Apollomics.

Apollomics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Apollomics

• Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer | Apollomics, Inc.
• Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion | Apollomics, Inc.
• Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75% | Apollomics, Inc.
• Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation | Apollomics, Inc.
• Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update | Apollomics, Inc.
• Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023 | Apollomics, Inc.
• Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference | Apollomics, Inc.
• Presentations | Apollomics, Inc.
• Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq | Apollomics, Inc.
• Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium | Apollomics, Inc.
• View more press releases Close

Redes sociais sobre Apollomics

• Apollomics na Wikipedia, Google News e Yahoo Finance
• Apollomics na LinkedIn, X (Twitter) e YouTube